Published in J Biol Chem on September 24, 2008
Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming enzymes. Nat Chem Biol (2009) 1.73
Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia. PLoS One (2010) 1.49
Conformational plasticity and structure/function relationships in cytochromes P450. Antioxid Redox Signal (2010) 1.40
Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 1.38
The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection. J Biol Chem (2009) 1.38
Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis. Trends Microbiol (2011) 1.30
The genome of Mycobacterium africanum West African 2 reveals a lineage-specific locus and genome erosion common to the M. tuberculosis complex. PLoS Negl Trop Dis (2012) 1.20
The structure and mechanism of the Mycobacterium tuberculosis cyclodityrosine synthetase. Nat Chem Biol (2010) 1.17
The Mycobacterium tuberculosis cytochrome P450 system. Arch Biochem Biophys (2009) 1.16
Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen. J Biol Chem (2010) 1.16
Biochemical and structural characterization of CYP124: a methyl-branched lipid omega-hydroxylase from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 1.13
CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani. PLoS One (2011) 0.89
Structure and biochemical properties of the alkene producing cytochrome P450 OleTJE (CYP152L1) from the Jeotgalicoccus sp. 8456 bacterium. J Biol Chem (2014) 0.89
Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines. J Biol Chem (2009) 0.86
Unusual spectroscopic and ligand binding properties of the cytochrome P450-flavodoxin fusion enzyme XplA. J Biol Chem (2012) 0.84
Genomic signatures of the haarlem lineage of Mycobacterium tuberculosis: implications of strain genetic variation in drug and vaccine development. J Clin Microbiol (2010) 0.82
Identification of small-molecule scaffolds for p450 inhibitors. Curr Protoc Microbiol (2010) 0.81
Oxidative Cyclization in Natural Product Biosynthesis. Chem Rev (2016) 0.81
Genome-wide transcription analyses in Mycobacterium tuberculosis treated with lupulone. Braz J Microbiol (2014) 0.79
Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: insights from biochemical studies and crystal structures. J Biol Chem (2013) 0.78
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors. J Med Chem (2016) 0.78
Structural and functional characterization of a cytochrome P450 2B4 F429H mutant with an axial thiolate-histidine hydrogen bond. Biochemistry (2014) 0.77
Structural characterization of CYP144A1 - a cytochrome P450 enzyme expressed from alternative transcripts in Mycobacterium tuberculosis. Sci Rep (2016) 0.76
Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Sci Rep (2016) 0.76
Genome-Wide Annotation and Comparative Analysis of Cytochrome P450 Monooxygenases in Basidiomycete Biotrophic Plant Pathogens. PLoS One (2015) 0.76
The MarR-like protein PchR (YvmB) regulates expression of genes involved in pulcherriminic acid biosynthesis and in the initiation of sporulation in Bacillus subtilis. BMC Microbiol (2016) 0.75
Molecular docking of azole drugs and their analogs on CYP121 of Mycobacterium tuberculosis. Bioinformation (2011) 0.75
Biosynthesis of Strained Piperazine Alkaloids - Uncovering the Concise Pathway of Herquline A. J Am Chem Soc (2016) 0.75
Rational and combinatorial tailoring of bioactive cyclic dipeptides. Front Microbiol (2015) 0.75
Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors. ChemMedChem (2016) 0.75
Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1. J Biol Chem (2016) 0.75
Crosslinking of Dicyclotyrosine by the Cytochrome P450 Enzyme CYP121 from Mycobacterium tuberculosis Proceeds through a Catalytic Shunt Pathway. J Biol Chem (2017) 0.75
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr (2005) 61.38
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
ARP/wARP and automatic interpretation of protein electron density maps. Methods Enzymol (2003) 6.37
Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A (2001) 6.22
Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology (2000) 5.00
Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A (2004) 4.78
Redox potentiometry: determination of midpoint potentials of oxidation-reduction components of biological electron-transfer systems. Methods Enzymol (1978) 4.48
Antifungal agents: mechanisms of action. Trends Microbiol (2003) 3.74
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A (2001) 2.90
Estriol bound and ligand-free structures of sterol 14alpha-demethylase. Structure (2004) 1.98
Pivotal role of water in the mechanism of P450BM-3. Biochemistry (2001) 1.81
New tuberculosis therapeutics: a growing pipeline. J Infect Dis (2007) 1.78
P450 BM3: the very model of a modern flavocytochrome. Trends Biochem Sci (2002) 1.77
Cryoradiolytic reduction of crystalline heme proteins: analysis by UV-Vis spectroscopy and X-ray crystallography. J Synchrotron Radiat (2006) 1.67
glnE is an essential gene in Mycobacterium tuberculosis. J Bacteriol (2000) 1.59
A thermodynamic model of regulation: modulation of redox equilibria in camphor monoxygenase. Proc Natl Acad Sci U S A (1976) 1.41
Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology (2002) 1.40
Gene expression diversity among Mycobacterium tuberculosis clinical isolates. Microbiology (2005) 1.36
Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem (2007) 1.33
Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry (1987) 1.31
Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450. J Biol Chem (2002) 1.31
Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett (2000) 1.26
Redox control of the catalytic cycle of flavocytochrome P-450 BM3. Biochemistry (1997) 1.22
Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem (2006) 1.21
Neutral thiol as a proximal ligand to ferrous heme iron: implications for heme proteins that lose cysteine thiolate ligation on reduction. Proc Natl Acad Sci U S A (2003) 1.20
Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization. Biochem J (1992) 1.19
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. J Bacteriol (2006) 1.17
Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis. J Inorg Biochem (2002) 1.15
Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3. Biochemistry (2001) 1.14
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett (2005) 1.13
The preponderance of P450s in the Mycobacterium tuberculosis genome. Trends Microbiol (2006) 1.11
Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett (2006) 1.09
Biophysical characterization of the sterol demethylase P450 from Mycobacterium tuberculosis, its cognate ferredoxin, and their interactions. Biochemistry (2006) 1.08
Phe393 mutants of cytochrome P450 BM3 with modified heme redox potentials have altered heme vinyl and propionate conformations. Biochemistry (2004) 1.04
CYP51-like gene of Mycobacterium tuberculosis actually encodes a P450 similar to eukaryotic CYP51. J Biochem (1998) 1.03
Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem Pharmacol (2001) 1.02
Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents (2006) 1.02
Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis. Tuberculosis (Edinb) (2008) 1.00
Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole. Microbiology (2005) 0.98
Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis. Biochemistry (2004) 0.97
Kinetic, spectroscopic and thermodynamic characterization of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA. Biochem J (2003) 0.94
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol (2007) 0.92
Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis. Curr Top Med Chem (2007) 0.91
Structural diversities of active site in clinical azole-bound forms between sterol 14alpha-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem (2004) 0.91
Mycobacterium tuberculosis FprA, a novel bacterial NADPH-ferredoxin reductase. Eur J Biochem (2002) 0.91
Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium. J Biol Chem (2007) 0.90
Resonance Raman study on the structure of the active sites of microsomal cytochrome P-450 isozymes LM2 and LM4. Eur J Biochem (1989) 0.84
Resonance Raman scattering of cytochrome P450 BM3 and effect of imidazole inhibitors. Biopolymers (2003) 0.81
The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A (2003) 6.79
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med (2003) 5.97
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol (2002) 5.96
Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology (2002) 5.17
On the origin of leprosy. Science (2005) 4.22
Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A (2007) 3.73
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res (2007) 3.45
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (2009) 3.39
Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J Clin Microbiol (2002) 3.32
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol (2002) 2.91
Atomic description of an enzyme reaction dominated by proton tunneling. Science (2006) 2.84
ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol (2004) 2.79
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog (2009) 2.76
Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet (2009) 2.76
Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol (2009) 2.72
TubercuList--10 years after. Tuberculosis (Edinb) (2010) 2.65
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun (2006) 2.56
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. Microbiology (2004) 2.40
Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol (2010) 2.36
Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun (2002) 2.35
Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) (2004) 2.33
The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature (2011) 2.32
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol (2007) 2.31
Probable zoonotic leprosy in the southern United States. N Engl J Med (2011) 2.22
Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med (2003) 2.08
Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog (2009) 1.96
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog (2008) 1.94
Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol (2005) 1.93
Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol (2004) 1.91
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis (2010) 1.89
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog (2007) 1.83
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta (2005) 1.81
Genome-wide comparison of medieval and modern Mycobacterium leprae. Science (2013) 1.81
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis (2011) 1.81
Phi29 polymerase based random amplification of viral RNA as an alternative to random RT-PCR. BMC Mol Biol (2008) 1.81
Control of enhanced Raman scattering using a DNA-based assembly process of dye-coded nanoparticles. Nat Nanotechnol (2008) 1.79
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med (2012) 1.78
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One (2010) 1.75
Characterization of the Shewanella oneidensis MR-1 decaheme cytochrome MtrA: expression in Escherichia coli confers the ability to reduce soluble Fe(III) chelates. J Biol Chem (2003) 1.74
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) (2005) 1.73
Analysis of whole-genome microarray replicates using mixed models. Bioinformatics (2003) 1.73
A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One (2013) 1.71
PknB kinase activity is regulated by phosphorylation in two Thr residues and dephosphorylation by PstP, the cognate phospho-Ser/Thr phosphatase, in Mycobacterium tuberculosis. Mol Microbiol (2003) 1.69
Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiol Lett (2003) 1.66
PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun (2003) 1.66
Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One (2008) 1.65
Evaluation of surface-enhanced resonance Raman scattering for quantitative DNA analysis. Anal Chem (2004) 1.65
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J Biol Chem (2005) 1.64
Genotypic analysis of Mycobacterium tuberculosis in Bangladesh and prevalence of the Beijing strain. J Clin Microbiol (2004) 1.63
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol (2005) 1.61
Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone. Cell Microbiol (2005) 1.56
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol (2005) 1.55
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. Infect Immun (2002) 1.54
Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother (2003) 1.54
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun (2006) 1.51
The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2007) 1.49
Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. Biochim Biophys Acta (2007) 1.49
Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med (2007) 1.48
Zoonotic Leprosy in the Southeastern United States. Emerg Infect Dis (2015) 1.48
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med (2007) 1.47
Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog (2011) 1.46
Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol (2005) 1.45
Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One (2010) 1.44
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.43
Evidence that the Streptomyces developmental protein WhiD, a member of the WhiB family, binds a [4Fe-4S] cluster. J Biol Chem (2004) 1.42
Biochemical and structural insights into bacterial organelle form and biogenesis. J Biol Chem (2008) 1.41
Reengineering orthogonally selective riboswitches. Proc Natl Acad Sci U S A (2010) 1.41
Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology (2002) 1.40
Mycobacterium tuberculosis and the host response. J Exp Med (2005) 1.40
Mycobacterium ulcerans disease (Buruli ulcer) in Mali: A new potential African endemic country. Acta Derm Venereol (2015) 1.39
Dynamics driving function: new insights from electron transferring flavoproteins and partner complexes. FEBS J (2007) 1.38
Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC Microbiol (2008) 1.38
The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection. J Biol Chem (2009) 1.38
Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology (2005) 1.38
A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. J Bacteriol (2007) 1.38
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 1.36
Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol Med (2012) 1.36
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc (2010) 1.35
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1. J Am Chem Soc (2011) 1.33
Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans. Chem Commun (Camb) (2003) 1.33
Structure and spectroscopy of the periplasmic cytochrome c nitrite reductase from Escherichia coli. Biochemistry (2002) 1.32
Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J Clin Microbiol (2005) 1.32
CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics (2004) 1.32
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One (2013) 1.31
Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother (2012) 1.31